|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
<http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W7C-513363B-6&_user=10&_coverDate=03%2F31%2F2011&_rdoc=15&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_srch=doc-info>(%23toc%236623%232011%23999459996%232908743%23FL
A%23display%23Volume)&_cdi=6623&_sort=d&_docanchor=&_ct=41&_acct=C000050221&_ver
sion=1&_urlVersion=0&_userid=10&md5=68f6f775eb072d035246254854fc79d4&searchtype=
a
Journal of Hepatology
Volume 54, Issue 3, March 2011, Pages 449-454
--------------------------------------------------------------------------------
doi:10.1016/j.jhep.2010.07.046 | How to Cite or Link Using DOI
Copyright © 2010 European Association for the Study of the Liver Published by
Elsevier Ireland Ltd. Permissions & Reprints
Research Article
Kinetics of hepatitis B surface antigen differ between treatment with
peginterferon and entecavir
References and further reading may be available for this article. To view
references and further reading you must purchase this article.
Jurriën G.P. Reijnders1, §, Vincent Rijckborst1, §, Milan J. Sonneveld1,
Sandra M.J. Scherbeijn2, Charles A.B. Boucher2, Bettina E. Hansen1, 3 and Harry
L.A. Janssen1, , 1 Department of Gastroenterology and Hepatology, Erasmus MC,
University Medical Center, Rotterdam, The Netherlands 2 Department of Virology,
Erasmus MC, University Medical Center, Rotterdam, The Netherlands 3 Department
of Biostatistics, Erasmus MC, University Medical Center, Rotterdam, The
Netherlands
Received 9 April 2010; revised 8 July 2010; accepted 12 July 2010. Available
online 23 September 2010.
Background & Aims
We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in
patients with chronic hepatitis B virus (HBV) infection during peginterferon
(PEG-IFN) and entecavir (ETV) monotherapy.
Methods
HBsAg was quantified (Abbott ARCHITECT) at baseline and during antiviral therapy
(weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-) positive patients
treated with ETV (n = 33) or PEG-IFN (n = 61) and in HBeAg-negative patients
treated with ETV (n = 37) or PEG-IFN (n = 69).
Results
Within the HBeAg-positive population, patients treated with PEG-IFN tended to
have a steeper HBsAg decline than ETV-treated patients (mean decline 0.94 versus
0.38 log IU/ml at week 48, p = 0.07 for comparison of the slope of HBsAg
decline). The HBsAg decline was larger in those patients who became HBeAg
negative, irrespective of the treatment regimen. A decline in HBsAg was confined
to ETV-treated patients with elevated baseline alanine aminotransferase (ALT)
levels, whereas HBsAg decline was not associated with baseline ALT in patients
treated with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a
significant HBsAg decline, while HBsAg did not decrease in ETV-treated patients
(0.56 versus −0.10 log IU/ml, p <0.001). Both in HBeAg-positive and
HBeAg-negative patients, the decline in serum HBV DNA was larger in patients who
received ETV as compared to patients treated with PEG-IFN.
Conclusions
In HBeAg-positive patients, the decline in serum HBsAg is mainly confined to
patients who clear HBeAg, by either PEG-IFN or ETV treatment. In HBeAg-negative
patients, PEG-IFN therapy resulted in a significant reduction in HBsAg levels,
whereas HBsAg did not decrease in ETV-treated patients.
|
|
发表于 2011-3-2 08:01